Trials: Prevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnC

Phase 3 N=938 Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)

Pneumococcal Infections

Primary: Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC Relative to 23vPS (Vax 1 / Year 0) — 81; 55; 55; 49 geometric mean titer

Wyeth is now a wholly owned subsidiary of Pfizer Results May 2011 3.3% serious AE View details

Phase 3 N=619 Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.

Vaccines, Pneumococcal

Primary: Percentage of Participants Achieving Predefined Meningococcal C Serum Bactericidal Assay (SBA) Titer of ≥ 1:8, and a Predefined Antibody Level for Diphtheria in 13vPnC…

Wyeth is now a wholly owned subsidiary of Pfizer Results Aug 2012 3.2% serious AE View details

Phase 3 N=604 Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.

Vaccines, Pneumococcal

Primary: Percentage of Participants Achieving Antibody Level ≥0.35 μg/mL in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series — 98.2; 98.2; 77.5; 87.1…

Wyeth is now a wholly owned subsidiary of Pfizer Results Aug 2012 4.1% serious AE View details

Phase 3 N=1,160 Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults

Pneumococcal Infections

Primary: TIV Comparisons: Percentage of Participants Achieving at Least a 4-fold Increase in the Titer of the Standard Hemagglutination Inhibition Assay (HAI) — 80.3; 78.6; 58.0…

Pfizer Results Feb 2012 0.8% serious AE View details

Phase 3 N=666 Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine

Vaccines, Pneumococcal

Primary: Percentage of Participants Achieving Antibody Level ≥0.35 μg/mL in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series — 94.4; 98.0; 87.3; 92.8…

Pfizer Results Feb 2013 2.6% serious AE View details

Phase 4 N=84,496 Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults

Pneumonia, Pneumococcal · Pneumococcal Infections · 13-valent Pneumococcal Vaccine

Primary: Number of Participants With First Episode of Confirmed Vaccine-type Community-acquired Pneumonia (VT-CAP) — 49; 90 participants — p=0.0006

Pfizer Results Oct 2014 0.9% serious AE View details

Phase 3 N=606 Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants

Vaccines, Pneumococcal

Primary: Percentage of Participants Reporting Pre-Specified Local Reactions — 32.1; 30.0; 30.4; 36.7 Percentage of Participants

Wyeth is now a wholly owned subsidiary of Pfizer Results Feb 2013 2.5% serious AE View details

Phase 3 N=613 Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants

Vaccines, Pneumococcal

Primary: Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria, Tetanus, Hemophilus Influenza Type b (Hib), Poliomyelitis (Type 1, 2, 3), Pertussis Toxin…

Wyeth is now a wholly owned subsidiary of Pfizer Results Aug 2012 1.5% serious AE View details

Phase 3 N=286 Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants

Vaccines, Pneumococcal

Primary: Percentage of Participants Achieving a Meningococcal C Serum Bactericidal Assay (SBA) Titer ≥1:8 and Predefined Antibody Levels for Pertussis and Haemophilus Influenzae…

Wyeth is now a wholly owned subsidiary of Pfizer Results Aug 2012 1.5% serious AE View details

Phase 3 N=709 Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India

Pneumococcal Infections

Primary: Percentage of Participants Achieving a Predefined Antibody Level of Greater Than or Equal to 0.35 Micrograms (Mcg)/mL, 1 Month After the Infant Series. — 97.0; 97.9…

Wyeth is now a wholly owned subsidiary of Pfizer Results Nov 2010 2.1% serious AE View details

Phase 3 N=118 Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Children

Pneumococcal Vaccines

Primary: Geometric Mean Concentration (GMC) of Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibodies 1 Month After the Toddler Dose — 5.27; 5.06; 9.63; 8.75 mcg/mL

Pfizer Results Jul 2011 1.3% serious AE View details

Phase 3 N=331 Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS

HIV Infections · Pneumococcal Infections

Primary: Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After Dose 2 of 13vPnC to 1 Month After Dose 3 of 13vPnC…

Pfizer Results Jun 2013 4.2% serious AE View details

Phase 3 N=449 Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants

Vaccines, Pneumococcal

Primary: Percentage of Participants Achieving a Serum Bactericidal Assay (SBA) Titer ≥ 1:8 in 13vPnC Group Relative to 7vPnC Group After the 2-dose NeisVac-C Infant Series…

Wyeth is now a wholly owned subsidiary of Pfizer Results Mar 2013 2.4% serious AE View details

Phase 3 N=355 Study Evaluating 13-valent Pneumococcal Conjugate Vaccine Catch-Up Regimens in Older Infants and Children

Pneumococcal Infections

Primary: Percentage of Participants Achieving Antibody Level ≥0.35μg/mL After Vaccination — 100.0; 100.0; 99.3; 98.8 percentage of participants

Wyeth is now a wholly owned subsidiary of Pfizer Results Aug 2012 2.5% serious AE View details

Phase 4 N=100 Study To Describe The Safety Of 13-valent Pneumococcal Conjugate Vaccine In Children 6 To 17 Years Of Age In India

Vaccines

Primary: Percentage of Participants Reporting Local Reactions by Severity Within 7 Days After Vaccination — 14.9; 14.9; 0; 0 percentage of participants

Pfizer Results Apr 2020 1.0% serious AE View details

Phase 3 N=720 Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS

Pneumococcal Vaccines

Primary: Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 23vPS (Year 1) Versus 23vPS (Year 0) — 148; 148; 125; 80 geometric mean titer

Wyeth is now a wholly owned subsidiary of Pfizer Results May 2011 1.5% serious AE View details

Phase 4 N=1,199 13-valent Pneumococcal Conjugate Vaccine Study in Adults and Children in India

Prevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnC

Primary: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) Within 1 Month After 13vPnC Vaccination — 0; 7; 0; 0 Percentage…

Pfizer Results Jul 2016 0.0% serious AE View details

Phase 3 N=1,200 Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years

Healthy Subjects

Primary: Percentage of Participants Achieving Predefined Serotype-specific Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal to (≥) 0.35 Micrograms Per…

Pfizer Results Aug 2011 0.5% serious AE View details

Phase 3 N=1,866 Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization

Pneumococcal Infections

Primary: Percentage of Participants With a New Acquisition of Serotype 6A' (6A + 6C) or 19A Combined 1 Month After the Infant Series to 24 Months of Age — 20.0; 36.0 percentage…

Pfizer Results Jul 2012 6.0% serious AE View details

Phase 3 N=500 13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants.

Pneumococcal Vaccines

Primary: Percentage of Participants Achieving a Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal To (>=) 0.35 Microgram Per…

Pfizer Results Mar 2015 0.1% serious AE View details

Phase 3 N=324 13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in Mexico

Pneumococcal Infections

Primary: Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination — 120; 84; 88; 89 titer

Pfizer Results Jan 2013 0.6% serious AE View details

Phase 3 N=373 Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.

Pneumococcal Disease · 13-valent Pneumococcal Vaccine

Primary: Percentage of Participants Achieving Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody Level ≥0.35 Micrograms Per Milliliter (Mcg/mL) 1 Month After the…

Pfizer Results Feb 2012 6.8% serious AE View details

Phase 3 N=89 Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine

Invasive Pneumococcal Disease

Primary: Percentage of Participants Achieving a Predefined Serotype-specific Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal to ( ≥) 0.35 Micrograms Per…

Wyeth is now a wholly owned subsidiary of Pfizer Results Jan 2011 0.0% serious AE View details

Phase 3 N=262 Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.

13-valent Pneumococcal Vaccine · Immunization · Safety

Primary: Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMC) 1 Month After Single Dose of 13 Valent Pneumococcal Conjugate (13vPnC) Vaccine…

Pfizer Results Feb 2012 0.0% serious AE View details

N/A N=53,902 Postlicensure Observational Safety Study of 13vPnC Administered to Infants and Toddlers

Pneumococcal Disease

Primary: Relative Risk of Medically Attended Events Between 30-day Risk Window and 30-day Self-control Window: Pre-Dose 1 Inpatient — 0.98; 0.46; 0.98; 0.30 ratio — p=0.98

Pfizer Results Jul 2014 View details

Phase 3 N=839 Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age

Pneumococcal Disease

Primary: Percentage of Participants Reporting Prompted Local Reactions Within 7 Days After Vaccination — 37.7; 39.1; 37.2; 15.1 Percentage of participants

Pfizer Results Apr 2023 0.6% serious AE View details

Phase 3 N=303 Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine

HIV Infections · Pneumococcal Infections

Primary: Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in All…

Pfizer Results Nov 2014 0.5% serious AE View details

Phase 3 N=603 Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants

Vaccines, Pneumococcal Conjugate Vaccine

Primary: Percentage of Subjects Achieving Predefined Antibody Level ≥1:8 for Meningococcal C Serum Bactericidal Assay (SBA) in the 13vPnC Group Relative to 7vPnC Group After 2…

Wyeth is now a wholly owned subsidiary of Pfizer Results Jun 2010 1.8% serious AE View details

Phase 3 N=168 Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered to Infants in Taiwan

Vaccines · Pneumococcal Conjugate Vaccine

Primary: Percentage of Participants Achieving a Predefined Antibody Level of Greater Than or Equal to 0.35 Micrograms (mcg)/mL, 1 Month After the Infant Series. — 98.8; 100.0…

Wyeth is now a wholly owned subsidiary of Pfizer Results May 2011 6.4% serious AE View details

Phase 4 N=882 Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.

PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE

Primary: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for 13 Pneumococcal Serotypes — 75; 83; 41; 49 titer

Pfizer Results Jul 2016 1.2% serious AE View details

Clinical Trial Search

Phase 3 N=938 Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)

Phase 3 N=619 Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.

Phase 3 N=604 Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.

Phase 3 N=1,160 Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults

Phase 3 N=666 Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine

Phase 4 N=84,496 Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults

Phase 3 N=606 Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants

Phase 3 N=613 Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants

Phase 3 N=286 Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants

Phase 3 N=709 Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India

Phase 3 N=118 Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Children

Phase 3 N=331 Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS

Phase 3 N=449 Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants

Phase 3 N=355 Study Evaluating 13-valent Pneumococcal Conjugate Vaccine Catch-Up Regimens in Older Infants and Children

Phase 4 N=100 Study To Describe The Safety Of 13-valent Pneumococcal Conjugate Vaccine In Children 6 To 17 Years Of Age In India

Phase 3 N=720 Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS

Phase 4 N=1,199 13-valent Pneumococcal Conjugate Vaccine Study in Adults and Children in India

Phase 3 N=1,200 Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years

Phase 3 N=1,866 Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization

Phase 3 N=500 13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants.

Phase 3 N=324 13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in Mexico

Phase 3 N=373 Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.

Phase 3 N=89 Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine

Phase 3 N=262 Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.

N/A N=53,902 Postlicensure Observational Safety Study of 13vPnC Administered to Infants and Toddlers

Phase 3 N=839 Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age

Phase 3 N=303 Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine

Phase 3 N=603 Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants

Phase 3 N=168 Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered to Infants in Taiwan

Phase 4 N=882 Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.